Oncologia, Speciale ASCO 2024

from Salute e Società · host Marco Caracciolo

1. Presentati al Congresso annuale dell'American Society of Clinical Oncology a Chicago i risultati di follow-up a lungo termine dello studio di Fase 3 CROWN che ha valutato l’utilizzo di lorlatinib. 2. Trastuzumab deruxtecan – anticorpo monoclonale farmaco-coniugato – può cambiare lo standard di cura in prima linea del tumore della mammella metastatico, evitando la chemioterapia dopo la terapia anti ormonale.

Episode metadata supplied by the publisher feed · Published Jun 22, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Oncologia, Speciale ASCO 2024

0:00 6:39

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Salute e Società?

This episode is 6 minutes long.

When was this Salute e Società episode published?

This episode was published on June 22, 2024.

Can I download this Salute e Società episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!